Stock Details
3349.T is COSMOS Pharmaceutical Corporation's stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 13,484.40๏ฟฅ. Average daily volumn in 3 months 234.69k. Market cap 449.45B



Stock symbol : 3349.T. Exchange : Tokyo. Currency : JPY
Lastest price : 11,350.00๏ฟฅ. Total volume : 179.70k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

COSMOS Pharmaceutical Corporation (3349.T)
Last Price
11,350.00๏ฟฅ
Change
110.00
Volume
179.70k

Previous Close11,240.00
Open11,320.00
Day Range11,270.00-11,500.00
Bid11,350.00 x N/A
Ask11,370.00 x N/A
Volume179.7k
Average Volume234.69k
Market Cap449.45B
Beta0.36
52 Week Range10,770.00-20,700.00
Trailing P/E20.40
Foward P/E17.59
Dividend (Yield %)0.71%
Ex-Dividend Date2022-05-30



Financial Details


According to COSMOS Pharmaceutical Corporation's financial reports the company's revenue in 2021 were 726.42B an increase( +6.14%) over the years 2020 revenue that were of 684.4B. In 2021 the company's total earnings were 27.16B while total earnings in 2020 were 21.43B( +28.57%).


Loading ...



Organization

COSMOS Pharmaceutical Corporation operates a chain of drug stores in Japan. It also operates 1,130 stores in the Kanto, Chubu, Kansai, Chugoku, Shikoku, and Kyushu regions. The company was founded in 1983 and is headquartered in Fukuoka, Japan.

Market Cap:
449.45B
Revenue:
726.42B
Total Assets:
341.32B
Total Cash:
55.11B


News about "COSMOS Pharmaceutical Corporation"

Cosmos Pharmaceutical Corp (3349)

Source from : Investing.com - 11 days ago

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...See details»


Cosmos Holdings Reports 12.5% Increase in Revenue, 88.9% Increase in Gross Profit and Achieves Profitability for the First Quarter of 2022

Source from : Yahoo - 3 days ago

2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals ...See details»


0RGI.L - Cosmo Pharmaceuticals NV Profile | Reuters

Source from : Reuters - 9 month ago

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses ...See details»


Cosmos Holdings Appoints Finance Veteran Dr. Anastasios Aslidis to the Board of Directors and as a Member of the Boardโ€™s Audit Committee

Source from : Digital Journal - 19 days ago

CHICAGO, IL / ACCESSWIRE / May 3, 2022 / Cosmos Holdings, Inc. (โ€œthe Companyโ€) (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor ...See details»


Cosmos Holdings Launches Mediterranation, a New Premium Nutritional Supplements Line

Source from : The Globe and Mail - 1 month ago

CHICAGO, IL / ACCESSWIRE / April 12, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor ...See details»


Cosmos Holdings to Launch Sky Premium Life Nutritional Supplements on Amazon Canada

Source from : Digital Journal - 17 days ago

CHICAGO, IL / ACCESSWIRE / May 5, 2022 / Cosmos Holdings, Inc. (โ€œthe Companyโ€) (Nasdaq:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor ...See details»


Cosmos Holdings, Inc. Reports Q1 Revenue of $13.07M, Net Income of $35K

Source from : Investing.com - 4 days ago

Cosmos Holdings Inc. (COSM) is an international pharmaceutical company, with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals ...See details»


COSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEWยฎ TO ALL COUNTRIES EXCEPT CANADA

Source from : dgap - 20 days ago

Dublin, Ireland - 3 May 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') announces the expansion of the agreement with Medtronic for the distribution of Eleview(R) to all countries ...See details»


Cosmos Holdings Reports Continued Revenue Growth and Achieves $3.3 Million of Adjusted EBITDA for the Fiscal Year 2021

Source from : Yahoo Finance - 1 month ago

CHICAGO, IL / ACCESSWIRE / April 19, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of ...See details»


Budesonides Market Size 2022 by Regional Production Volume, Drivers, Opportunities, Revenue, Growth Rate and Forecast to 2029

Source from : MarketWatch - 24 days ago

and Company Profiles. The report describes trends, cost, value, income and gross productivity of the Budesonides industry. Key players in the global Budesonides market covered in Chapter 2 and ...See details»


corporate-radar-q4-results-rights-issue-bonus-more-image

Corporate Radar: Q4 results, rights issue, bonus & more

Source from : India Times - 14 days ago

Today is the record date for NCL Research and Financial Services' rights issue. The company had announced a rights issue in the 21:25 ratio.See details»


COSMOS Pharmaceutical Corp.

Source from : Wall Street Journal - 10 days ago

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...See details»


COSMOS Pharmaceutical Corp - Stock Quote 3349

Source from : Morningstar%2c Inc. - 1 month ago

There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...See details»


Cosmos Holdings Reports 12.5% Increase in Revenue, 88.9% Increase in Gross Profit and Achieves Profitability for the First Quarter of 2022

Source from : Big News Network.com - 4 days ago

Reports Positive Net Income of $0.2 Million and $1.2 Million of EBITDA for the First Quarter of 2022. CHICAGO, IL / ACCESSWIRE / May 18, 2022 / Cosmos Holdings, Inc. ('the Company ...See details»